Results 31 to 40 of about 745,289 (215)
Immuno Magnetic Thermosensitive Liposomes For Cancer Therapy [PDF]
, 2019 The present work describes the encapsulation of the drug doxorubicin (DOX) in immuno paramagnetic thermosensitive liposomes. DOX is the most common chemotherapeutic agent for the treatment of a variety of carcinomas.
Alawak, Mohamad
core +1 more source
Antibody–drug Conjugates: Using Monoclonal Antibodies for Delivery of Cytotoxic Payloads to Cancer Cells [PDF]
Therapeutic Delivery, 2011 One approach to improving activity of anticancer drugs is to conjugate them to antibodies that recognize tumor-associated, cell-surface antigens. The antibody-drug conjugate concept evolved following major advances, first, in the development of humanized and fully human antibodies; second, in the discoveries of highly cytotoxic compounds ('drugs ...
Victor S, Goldmacher, Yelena V, Kovtun
openaire +2 more sources
Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. [PDF]
, 2017 INTRODUCTION: Colorectal cancer remains the second leading cause of cancer death in the United States, and new strategies to prevent, detect, and treat the disease are needed.
Aka, Allison A. +5 more
core +2 more sources
Cancers, 2022 Simple Summary Many cancer drugs are cytotoxic, which means that they kill cancer cells effectively but are also toxic to normal cells. To overcome this problem, we designed a novel compound, VIP236, which consists of three components.
H. Lerchen +10 more
semanticscholar +1 more source
A spoonful of sugar: the application of glycopolymers in therapeutics [PDF]
, 2011 Glycopolymers, synthetic polymers displaying carbohydrate moieties, have been linked to many potential applications at the biology–chemistry interface. One area that holds particular promise is the employment of glycopolymers as vehicles for therapeutics
Cameron, Neil R., Spain, Sebastian G.
core +2 more sources
Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates
Molecular Cancer Therapeutics, 2021 After several notable clinical failures in early generations, antibody–drug conjugates (ADC) have made significant gains with seven new FDA approvals within the last 3 years.
Eshita Khera +5 more
semanticscholar +1 more source
Antibody–drug conjugates: Recent advances in linker chemistry
Acta Pharmaceutica Sinica B, 2021 Antibody–drug conjugates (ADCs) are gradually revolutionizing clinical cancer therapy. The antibody–drug conjugate linker molecule determines both the efficacy and the adverse effects, and so has a major influence on the fate of ADCs.
Zheng Su +7 more
doaj +1 more source
Albumin-heparin microspheres as carriers for cytostatic agents [PDF]
, 1990 Much work has been done on adriamycin-loaded albumin microspheres (Alb-MS) for chemoembolization [1–4], the rationale being that site-specific drug delivery may increase the therapeutic efficacy of the drug. Alb-Ms are being investigated because of their
Bae, Y.H. +6 more
core +2 more sources
Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase. [PDF]
, 2019 Nucleic Acid Therapeutics (NATs), including siRNAs and AntiSense Oligonucleotides (ASOs), have great potential to drug the undruggable genome. Targeting siRNAs and ASOs to specific cell types of interest has driven dramatic improvement in efficacy and ...
Cui, Xianshu +6 more
core +1 more source
Clinical Cancer Research, 2022 PURPOSE Small Molecule-Drug Conjugates (SMDCs) are modular anti-cancer pro-drugs that include a tumor-targeting small organic ligand, a cleavable linker and a potent cytotoxic agent.
Aureliano Zana +16 more
semanticscholar +1 more source